The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1162
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The full article is available to subscribers Subscriber Login   
Aprepitant (Emend - Merck), the first substance P/neurokinin 1 (NK1) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT3) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin. ... more
     
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
Article code: 1162b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian